



CSD/BSE&NSE/2022-23  
November 10, 2022

To  
The General Manager  
Department of Corporate Services  
BSE Limited  
25th Floor, P. J. Towers,  
Dalal Street, Mumbai - 400 001

To  
The Manager  
Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza, Bandra Kurla Complex  
Bandra (E), Mumbai – 400 051

Scrip Code: 530239

Scrip Symbol: SUVEN

Dear Sir/Madam,

**Sub: Statement of Deviation(s) or variation(s) for quarter ended 30<sup>th</sup> September, 2022 under Regulation 32 of SEBI (LODR) Regulations, 2015.**

.....

With reference to the above subject, please find enclosed statement confirming that there were no deviation(s) or variation(s) in the use of proceeds, from the objects for which funds were raised through the preferential issue made by the Company, for the quarter ended 30<sup>th</sup> September, 2022.

We request you to take this on your record.

Thanking you,

Yours faithfully,  
For **Suven Life Sciences Limited**

**SHRENIK** Digitally signed by  
SHRENIK SONI  
**SONI** Date: 2022.11.10  
17:43:25 +05'30'

**Shrenik Soni**  
Company Secretary  
Encl.: as above

## Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7  
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713  
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: [info@suven.com](mailto:info@suven.com) website: [www.suven.com](http://www.suven.com)

Statement of Deviation / Variation in utilisation of funds raised						
Name of listed entity	Suven Life Sciences Limited					
Mode of Fund Raising	Preferential Issue					
Date of Raising Funds	02/04/2021					
Total Amount Raised (in Rs. crores)	Rs. 147.6417 Crore being total consideration amount of preferential issue size.					
Report filed for Quarter ended	30 <sup>th</sup> September, 2022					
Monitoring Agency	Not Applicable					
Monitoring Agency Name, if applicable	Not Applicable					
Is there a Deviation / Variation in use of funds raised	No					
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	Not Applicable					
If Yes, Date of shareholder Approval	Not Applicable					
Explanation for the Deviation / Variation	Not Applicable					
Comments of the Audit Committee after review	Nil					
Comments of the auditors, if any	Not Applicable					
Objects for which funds have been raised and where there has been a deviation, in the following table	The proceeds of the preferential issue shall be utilized to meet the funding requirements of the company for undertaking Research & Development activities, general corporate purposes and working capital requirements.					
Original Object	Modified Object, if any	Original Allocation (A)	Modified allocation, if any	Funds Utilised (B)	Amount of Deviation/ Variation for the quarter according to applicable object	Remarks if any
The proceeds of the preferential issue shall be utilized to meet the funding requirements of the company for undertaking Research & Development activities, general corporate purposes and working capital requirements.	Not Applicable	Rs. 147.6417 Crore	Not Applicable	Rs. 147.6417 Crore	Not Applicable	The amount raised through Preferential Issue was fully utilized as on quarter ended 30/09/2022.

*Deviation or variation could mean:*

- (a) Deviation in the objects or purposes for which the funds have been raised or*
- (b) Deviation in the amount of funds actually utilized as against what was originally disclosed or*
- (c) Change in terms of a contract referred to in the fund raising document i.e. prospectus, letter of offer, etc*

**For Suven Life Sciences Limited**

*M. Mohan*

**M. Mohan Kumar**  
Chief Financial Officer

